2024-04-24  12:40:49 PM Chg. -0.590 Volume Bid12:40:56 PM Ask12:40:56 PM Market Capitalization Dividend Y. P/E Ratio
62.340EUR -0.94% 2,408
Turnover: 150,401.550
62.200Bid Size: 240 62.340Ask Size: 240 78.04 bill.EUR - -

Business description

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
 

Management board & Supervisory board

CEO
Daniel O’Day
Management board
Andrew Dickinson, Jyoti Mehra, Stacey Ma, Flavius Martin, Johanna Mercier, Johanna Mercier, Cindy Perettie, Deborah H. Telman
Supervisory board
Daniel O’Day, Jacqueline K. Barton, Jeffrey A. Bluestone, Sandra J. Horning, Kelly A. Kramer, Kevin E. Lofton, Harish Manwani, Harish Manwani, Anthony Welters
 

Company data

Name: Gilead Sciences Inc.
Address: 333 Lakeside Drive,Foster City, California 94404, USA
Phone: +1-650-574-3000
Fax: +1-650-578-9264
E-mail: corporate_communicat...ead.com corporate_communications@gilead.com
Internet: www.gilead.com
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12-31
Free Float: 55.84%
IPO date: 1992-01-22

Investor relations

Name: Jacquie Ross
IR phone: +1-650-524-7792
IR Fax: -
IR e-mail: investor_relations@gilead.com

Company calendar

CW 17 | 2024-04-25 Interim Report 1st Quarter/3 Months
CW 19 | 2024-05-08 General Shareholder Meeting
 

Main Shareholders

Others
 
55.84%
Blackrock Inc.
 
10.13%
Vanguard Group Inc
 
9.10%
Capital World Investors
 
6.50%
State Street Corporation
 
4.76%
Capital Research Global Investors
 
4.65%
Dodge & Cox Inc
 
2.73%
Geode Capital Management, LLC
 
1.94%
FMR, LLC
 
1.61%
Others
 
2.74%